occurred at 137 centers throughout the world in the phase 3 trial, which suggests that the skills necessary to safely administer the combination therapy are widely available.

Furthermore, and to Valsecchi’s point, among the 120 patients who discontinued combination therapy because of toxic effects, the response rate was 67.5%. To us, this supports the current guidelines for management of toxic effects and discontinuation of treatment, since it shows that high response rates can be observed in the context of no treatment-related deaths. Longer follow-up will be needed to assess the effect of treatment discontinuation on overall survival.

James Larkin, M.D., Ph.D.
Royal Marsden Hospital
London, United Kingdom

F. Stephen Hodi, M.D.
Dana–Farber Cancer Institute
Boston, MA

Jedd D. Wolchok, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center
New York, NY
wolchokj@mskcc.org

Since publication of their article, the authors report no further potential conflict of interest.


DOI: 10.1056/NEJMc1509660

Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

TO THE EDITOR: In their report on the PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients with Prior Heart Attack using Ticagrelor Compared to Placebo on the Background of Aspirin-Thrombolysis in Myocardial Infarction 54) trial, Bonaca et al. (May 7 issue) suggest that the benefit of dual antiplatelet therapy comes at a cost of an increased risk of bleeding events. A dual antiplatelet regimen administered at an even lower dose than the one used in this study could confer a reduced risk of bleeding events and improved secondary prophylaxis against recurrent ischemic events as compared with aspirin.

We successfully tested a strategy of alternate-day administration of clopidogrel 1 year after percutaneous coronary intervention with placement of a drug-eluting stent. We hypothesized that the degree of antiplatelet effect that was required to prevent very late stent thrombosis decreases with time as the stent undergoes endothelialization — in other words, the therapeutic threshold that is required to prevent very late stent thrombosis decreases with time. The antiplatelet effect of clopidogrel lasts 5 to 7 days. Typically, after the interruption of clopidogrel therapy, stent thrombosis occurs after 3 to 4 days, which signifies the recovery of enough platelet function to produce stent thrombosis (i.e., above the therapeutic threshold). The use of clopidogrel every other day or a lower dose of ticagrelor among patients receiving a drug-eluting stent may be sufficient to cross the much reduced therapeutic threshold that is required to prevent very late stent thrombosis after 1 year and to avert recurrent coronary events from spontaneous plaque rupture without much bleeding risk (a so-called Goldilocks dose).

Sanjiv Sharma, M.D.
Bakersfield Heart Hospital
Bakersfield, CA
sanjiv1122@yahoo.com

Navneet Kaur, M.D.
Central Cardiology Medical Clinic
Bakersfield, CA

Rohan Sharma
University of California, Los Angeles
Los Angeles, CA

Dr. Sharma reports receiving lecture fees from Eli Lilly and Daiichi Sankyo and being an investigator for the PEGASUS-TIMI 54 trial. No other potential conflict of interest relevant to this letter was reported.


DOI: 10.1056/NEJMc1508692

TO THE EDITOR: Bonaca et al. report higher rates of cancer-related death among patients receiving either 90 mg or 60 mg of ticagrelor than among those receiving placebo (1.10% and 0.92% vs. 0.76%) (Table S2 in the Supplementary Appendix, The New England Journal of Medicine
Downloaded from nejm.org at UNIVERSITAETSBIBLIOTHEK BERN on April 5, 2016. For personal use only. No other uses without permission.
Copyright © 2015 Massachusetts Medical Society. All rights reserved.
available with the full text of the article at NEJM.org). Similar findings have been reported by Mauri et al.¹ with an extended use of thienopyridines beyond 1 year.

A pooled analysis of these two studies suggests a significant relative increase of 41% in the number of cancer-related deaths among patients who were treated with extended dual antiplatelet therapy (Fig. 1). In this analysis, the number of patients who would need to be treated to cause one cancer death was 322. Could the author indicate whether there was an imbalance in the diagnosis of cancer before and after randomization in the two study groups? If this is not the case, the reason for an increase in cancer-related deaths with an extended duration of dual antiplatelet therapy should be investigated.

Francesco Costa, M.D.
Erasmus Medical Center
Rotterdam, the Netherlands
Marco Valgimigli, M.D., Ph.D.
Swiss Cardiovascular Center
Bern, Switzerland
marco.valgimigli@insel.ch

No potential conflict of interest relevant to this letter was reported.


DOI: 10.1056/NEJMc1508692

TO THE EDITOR: Bonaca et al. are missing the most important finding of the PEGASUS-TIMI 54 study — namely, that drugs that cause excess bleeding also increase the risk of solid cancers. This study showed an increasing dose–response relationship for deaths from cancer: 77 in the group receiving 90 mg of ticagrelor and 64 in those receiving 60 mg of ticagrelor, as compared with 53 receiving placebo. In the Study of Platelet Inhibition and Patient Outcomes (PLATO), the administration of ticagrelor was too short and the follow-up was too incomplete to provide reliable data about cancer.¹

A review of prasugrel by the Food and Drug Administration (FDA)² first reported the association between bleeding and solid cancers. In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38),³ the hazard ratios in the prasugrel group, as compared with the clopidogrel group, for the incidence of solid cancers and death were both approximately 1.6 (P=0.001). An FDA review⁴ of the DAPT study documented that the relative risk of the incidence of a solid cancer was about 1.2 with clopidogrel and 1.3 with prasugrel, as compared with placebo. The rates of cancer-related death (relative risk, 2.2; P=0.02) were higher with continued use of thienopyridines.⁵ The latter FDA review⁴ also provides an

<table>
<thead>
<tr>
<th>Study</th>
<th>Extended Therapy</th>
<th>Standard Therapy</th>
<th>Hazard Ratio (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauri et al.</td>
<td>25/5012</td>
<td>14/4940</td>
<td>1.76 (0.92–3.39)</td>
<td></td>
</tr>
<tr>
<td>Bonaca et al.</td>
<td>141/14,095</td>
<td>53/7067</td>
<td>1.33 (0.97–1.83)</td>
<td></td>
</tr>
<tr>
<td>All patients</td>
<td>166/19,107</td>
<td>67/12,007</td>
<td>1.41 (1.06–1.87)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Heterogeneity, I²=0%

Figure 1. Pooled Analysis of Cancer-Related Deaths among Patients Receiving Extended Dual Antiplatelet Therapy, as Compared with Standard Therapy, in Two Studies.

In the trial by Mauri et al. (Dual Antiplatelet Therapy [DAPT] study), patients who had received 1 year of treatment with a thienopyridine (clopidogrel or prasugrel) were randomly assigned to continue receiving a thienopyridine or to receive a placebo for another 18 months. In the trial by Bonaca et al. (PEGASUS-TIMI 54), all patients were followed for a median of 33 months, including those receiving ticagrelor (who are included in the extended-therapy group in the pooled analysis) and those receiving placebo (who are included in the standard-therapy group). The size of the squares is proportional to the size of the study. The diamond incorporates the overall hazard ratio and 95% confidence interval.